Using pulmozyme dnase treatment in lentiviral vector production

Aaron Shaw, Daniela Bischof, Aparna Jasti, Aaron Ernstberger, Troy Hawkins, Kenneth Cornetta

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In the production of lentiviral vector for clinical studies the purity of the final product is of vital importance. To remove plasmid and producer cell line DNA, investigators have incubated the vector product with Benzonase, a bacterially derived DNase. As an alternative we investigated the use of Pulmozyme, a U.S. Food and Drug Administration-approved human DNase for the treatment of cystic fibrosis, by comparing the efficiency of DNA removal from lentiviral vector preparations. A green fluorescent protein-expressing lentiviral vector was prepared by transient calcium phosphate transfection of HEK 293T cells and DNA removal was compared when treating vector after harvest or immediately after transfection. The effectiveness of DNase treatment was measured by quantitative PCR using primers for vesicular stomatitis virus glycoprotein G viral envelope plasmid. When treating the final product, 1-hr incubations (37 C) with Pulmozyme at 20 U/ml reduced plasmid DNA to undetectable levels. Longer incubations (up to 4 hr) did not improve DNA removal at lower concentrations and the effectiveness was equivalent to or better than Benzonase at 50 U/ml. Attempting to use Pulmozyme immediately after transfection, but before final medium change, as a means to decrease Pulmozyme concentration in the final product provided a 2-log reduction in DNA but was inferior to treatment at the end of production. Pulmozyme, at concentrations up to 100 U/ml, had no measurable effect on infectious titer of the final vector product. The use of Pulmozyme is likely to increase the cost of DNase treatment when preparing vector product and should be considered when generating clinical-grade vector products.

Original languageEnglish
Pages (from-to)65-71
Number of pages7
JournalHuman gene therapy methods
Volume23
Issue number1
DOIs
StatePublished - Feb 1 2012

Fingerprint

Deoxyribonucleases
Serratia marcescens nuclease
DNA
Transfection
Plasmids
Vesicular Stomatitis
HEK293 Cells
United States Food and Drug Administration
Green Fluorescent Proteins
Cystic Fibrosis
Health Care Costs
dornase alfa
Glycoproteins
Research Personnel
Viruses
Cell Line
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Molecular Medicine
  • Applied Microbiology and Biotechnology
  • Genetics(clinical)
  • Genetics
  • Pharmacology
  • Medicine(all)

Cite this

Using pulmozyme dnase treatment in lentiviral vector production. / Shaw, Aaron; Bischof, Daniela; Jasti, Aparna; Ernstberger, Aaron; Hawkins, Troy; Cornetta, Kenneth.

In: Human gene therapy methods, Vol. 23, No. 1, 01.02.2012, p. 65-71.

Research output: Contribution to journalArticle

Shaw, A, Bischof, D, Jasti, A, Ernstberger, A, Hawkins, T & Cornetta, K 2012, 'Using pulmozyme dnase treatment in lentiviral vector production', Human gene therapy methods, vol. 23, no. 1, pp. 65-71. https://doi.org/10.1089/hgtb.2011.204
Shaw, Aaron ; Bischof, Daniela ; Jasti, Aparna ; Ernstberger, Aaron ; Hawkins, Troy ; Cornetta, Kenneth. / Using pulmozyme dnase treatment in lentiviral vector production. In: Human gene therapy methods. 2012 ; Vol. 23, No. 1. pp. 65-71.
@article{2b9cefbe53784ec597e3379763029904,
title = "Using pulmozyme dnase treatment in lentiviral vector production",
abstract = "In the production of lentiviral vector for clinical studies the purity of the final product is of vital importance. To remove plasmid and producer cell line DNA, investigators have incubated the vector product with Benzonase, a bacterially derived DNase. As an alternative we investigated the use of Pulmozyme, a U.S. Food and Drug Administration-approved human DNase for the treatment of cystic fibrosis, by comparing the efficiency of DNA removal from lentiviral vector preparations. A green fluorescent protein-expressing lentiviral vector was prepared by transient calcium phosphate transfection of HEK 293T cells and DNA removal was compared when treating vector after harvest or immediately after transfection. The effectiveness of DNase treatment was measured by quantitative PCR using primers for vesicular stomatitis virus glycoprotein G viral envelope plasmid. When treating the final product, 1-hr incubations (37 C) with Pulmozyme at 20 U/ml reduced plasmid DNA to undetectable levels. Longer incubations (up to 4 hr) did not improve DNA removal at lower concentrations and the effectiveness was equivalent to or better than Benzonase at 50 U/ml. Attempting to use Pulmozyme immediately after transfection, but before final medium change, as a means to decrease Pulmozyme concentration in the final product provided a 2-log reduction in DNA but was inferior to treatment at the end of production. Pulmozyme, at concentrations up to 100 U/ml, had no measurable effect on infectious titer of the final vector product. The use of Pulmozyme is likely to increase the cost of DNase treatment when preparing vector product and should be considered when generating clinical-grade vector products.",
author = "Aaron Shaw and Daniela Bischof and Aparna Jasti and Aaron Ernstberger and Troy Hawkins and Kenneth Cornetta",
year = "2012",
month = "2",
day = "1",
doi = "10.1089/hgtb.2011.204",
language = "English",
volume = "23",
pages = "65--71",
journal = "Human gene therapy methods",
issn = "1946-6536",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Using pulmozyme dnase treatment in lentiviral vector production

AU - Shaw, Aaron

AU - Bischof, Daniela

AU - Jasti, Aparna

AU - Ernstberger, Aaron

AU - Hawkins, Troy

AU - Cornetta, Kenneth

PY - 2012/2/1

Y1 - 2012/2/1

N2 - In the production of lentiviral vector for clinical studies the purity of the final product is of vital importance. To remove plasmid and producer cell line DNA, investigators have incubated the vector product with Benzonase, a bacterially derived DNase. As an alternative we investigated the use of Pulmozyme, a U.S. Food and Drug Administration-approved human DNase for the treatment of cystic fibrosis, by comparing the efficiency of DNA removal from lentiviral vector preparations. A green fluorescent protein-expressing lentiviral vector was prepared by transient calcium phosphate transfection of HEK 293T cells and DNA removal was compared when treating vector after harvest or immediately after transfection. The effectiveness of DNase treatment was measured by quantitative PCR using primers for vesicular stomatitis virus glycoprotein G viral envelope plasmid. When treating the final product, 1-hr incubations (37 C) with Pulmozyme at 20 U/ml reduced plasmid DNA to undetectable levels. Longer incubations (up to 4 hr) did not improve DNA removal at lower concentrations and the effectiveness was equivalent to or better than Benzonase at 50 U/ml. Attempting to use Pulmozyme immediately after transfection, but before final medium change, as a means to decrease Pulmozyme concentration in the final product provided a 2-log reduction in DNA but was inferior to treatment at the end of production. Pulmozyme, at concentrations up to 100 U/ml, had no measurable effect on infectious titer of the final vector product. The use of Pulmozyme is likely to increase the cost of DNase treatment when preparing vector product and should be considered when generating clinical-grade vector products.

AB - In the production of lentiviral vector for clinical studies the purity of the final product is of vital importance. To remove plasmid and producer cell line DNA, investigators have incubated the vector product with Benzonase, a bacterially derived DNase. As an alternative we investigated the use of Pulmozyme, a U.S. Food and Drug Administration-approved human DNase for the treatment of cystic fibrosis, by comparing the efficiency of DNA removal from lentiviral vector preparations. A green fluorescent protein-expressing lentiviral vector was prepared by transient calcium phosphate transfection of HEK 293T cells and DNA removal was compared when treating vector after harvest or immediately after transfection. The effectiveness of DNase treatment was measured by quantitative PCR using primers for vesicular stomatitis virus glycoprotein G viral envelope plasmid. When treating the final product, 1-hr incubations (37 C) with Pulmozyme at 20 U/ml reduced plasmid DNA to undetectable levels. Longer incubations (up to 4 hr) did not improve DNA removal at lower concentrations and the effectiveness was equivalent to or better than Benzonase at 50 U/ml. Attempting to use Pulmozyme immediately after transfection, but before final medium change, as a means to decrease Pulmozyme concentration in the final product provided a 2-log reduction in DNA but was inferior to treatment at the end of production. Pulmozyme, at concentrations up to 100 U/ml, had no measurable effect on infectious titer of the final vector product. The use of Pulmozyme is likely to increase the cost of DNase treatment when preparing vector product and should be considered when generating clinical-grade vector products.

UR - http://www.scopus.com/inward/record.url?scp=84872028045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872028045&partnerID=8YFLogxK

U2 - 10.1089/hgtb.2011.204

DO - 10.1089/hgtb.2011.204

M3 - Article

VL - 23

SP - 65

EP - 71

JO - Human gene therapy methods

JF - Human gene therapy methods

SN - 1946-6536

IS - 1

ER -